{"id":"W3165566500","doi":"10.1016/s2352-3026(21)00102-2","title":"Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial","year":2021,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":160,"is_retracted":false,"has_abstract":false,"ca_institutions":"Spinal Cord Injury BC","funders":"Pharmacyclics; Genentech; Bayer Fund; Seattle Genetics; Janssen Pharmaceuticals; Gilead Sciences; Roche; Johnson and Johnson; AbbVie; Merck; Celgene; Bristol-Myers Squibb; AstraZeneca; Takeda Pharmaceuticals U.S.A.; Pfizer","keywords":"Medicine; Brentuximab vedotin; Open label; Oncology; Internal medicine; Chemotherapy; Hodgkin lymphoma; Phases of clinical research; Lymphoma; Randomized controlled trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003238048,0.001518933,0.003138161,0.0003500423,0.0003575793,0.00182098,0.0009613291,0.001761071,0.004928714],"category_scores_gemma":[0.002677021,0.0005358216,0.002965965,0.0004706974,0.001040216,0.001928216,0.0005240748,0.004719037,0.001007167],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001035677,"about_ca_system_score_gemma":0.0008350974,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001180023,"about_ca_topic_score_gemma":0.003300142,"domain_scores_codex":[0.9988428,0.0006537623,0.0000686727,0.000154666,0.00009487222,0.0001850746],"domain_scores_gemma":[0.9986992,0.0005057884,0.0002979867,0.000107375,0.00007830069,0.0003113112],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9112896,0.002619123,0.001335863,0.002680375,0.003915055,0.000082661,0.0001866701,0.000884142,0.003067323,0.0004913296,0.00403512,0.06941271],"study_design_scores_gemma":[0.9551786,0.03523032,0.003027996,0.0002378279,0.001279675,0.00009699963,0.00005561409,0.0004449669,0.0003778997,0.0005837424,0.00345367,0.00003272272],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9096637,0.06628915,0.002745735,0.003710447,0.002911295,0.003490239,0.003591151,0.0003639806,0.007234285],"genre_scores_gemma":[0.9565982,0.02154626,0.003373503,0.00520597,0.0007495656,0.002984535,0.003676099,0.0001026576,0.005763379],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004928714,"threshold_uncertainty_score":0.01712465,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07474879554476967,"score_gpt":0.3914699568134968,"score_spread":0.3167211612687272,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}